Cohort Studyhigh evidence
Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease.
Journal of hepatology·June 1, 2026·PMID 41747774
Why it mattersFGF21 analogs are already in trials for fatty liver disease, but their impact on alcohol outcomes was unknown. This genetic evidence suggests they may uniquely reduce hazardous drinking and alcohol-related liver injury, addressing a major unmet need in patients with co-occurring alcohol use and metabolic liver disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled